---
layout: post
title: New Drug Approvals - Pt. XIX - Pralatrexate (Folotyn)
date: '2009-10-01T21:39:00.032+01:00'
author: Patricia
tags:
- 2009 New Drugs
modified_time: '2010-01-17T08:06:13.612Z'
thumbnail: http://3.bp.blogspot.com/_SlPG9DIz_AA/S1LE7NRGoyI/AAAAAAAAApE/S7fOZ93Xu-Y/s72-c/folotyn_73559_73560.jpg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-5522532463799319229
blogger_orig_url: http://chembl.blogspot.com/2009/10/new-drug-approvals-pt-xix-pralatrexate.html
---

<div class="separator" style="clear: both; text-align: center;"><a href="http://3.bp.blogspot.com/_SlPG9DIz_AA/S1LE7NRGoyI/AAAAAAAAApE/S7fOZ93Xu-Y/s1600-h/folotyn_73559_73560.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://3.bp.blogspot.com/_SlPG9DIz_AA/S1LE7NRGoyI/AAAAAAAAApE/S7fOZ93Xu-Y/s320/folotyn_73559_73560.jpg" /></a><br />
</div><div class="separator" style="clear: both; text-align: center;"><br />
</div><a href="http://1.bp.blogspot.com/_GrFxGiayAGE/Ssugx3iwPbI/AAAAAAAAAVs/CxhUh4Nl9kE/s1600-h/Pralatrexate_Icons.png" onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5389578157662682546" src="http://1.bp.blogspot.com/_GrFxGiayAGE/Ssugx3iwPbI/AAAAAAAAAVs/CxhUh4Nl9kE/s400/Pralatrexate_Icons.png" style="cursor: pointer; display: block; height: 45px; margin: 0px auto 10px; text-align: center; width: 400px;" /></a> Also approved on September 25th was Pralatrexate (tradename Folotyn). Pralatrexate is the first drug approved for the treatment of <a href="http://en.wikipedia.org/wiki/Peripheral_T-cell_lymphoma">Peripheral T-Cell Lymphoma (PTCL)</a>, an aggressive form of <a href="http://en.wikipedia.org/wiki/Non-Hodgkin_lymphoma">non-Hodgkins lymphoma</a>. Lymphoma is a cancer that begins in the lymphocytes of the immune system. PTCL is a rare disease, occurring in around 9,500 patients each year in the United States. <br />
Pralatrexate, also known as PDX, is a folic analog that competitively inhibits <a href="http://www.uniprot.org/uniprot/P00374">dihydrofolate reductase</a> (DHFR). Since Pralatrexate blocks the use/function of a metabolite, it is also an <a href="http://en.wikipedia.org/wiki/Antimetabolite">antimetabolite</a>. Pralatraxate has high affinity for the folate transporter <a href="http://www.uniprot.org/uniprot/P41440">SLC19A1</a> (also known as RFC-1), and so is an example of a drug that is 'actively transported', and is also a substrate for polyglutamation by the enzyme <a href="http://www.uniprot.org/uniprot/Q5JU19">folylpolyglutamate synthase</a> (FPGS). Once polyglutamated Pralatrexate has a prolonged intracellular half-life, giving prolonged action in malignant cells. Pralatrexate is related to several other drugs, most notably <a href="http://en.wikipedia.org/wiki/Methotrexate">Methotrexate</a>, and 'old' launched drug, and also the clinical stage compounds - Ketotrexate, Edatrexate, and also the antiprotozoal agent <a href="http://en.wikipedia.org/wiki/Trimetrexate">Trimetrexate</a>, all of which are DHFR inhibitors. <br />
Pralatrexate is a polar, racemic small molecule (Molecular Weight of 477.5 g.mol-1), soluble in aqueous solutions. Pralatrexate is a mixture of diastereomers (stereoisomers that are not enantiomers, i.e. they are non-superimposable). <a href="http://en.wikipedia.org/wiki/Diastereomer">Diastereomers</a> can have different physical properties biological activities, and different reactivity. Pralatrexate has a volume of distribution (Vd) of 105L and 37L for the S- and R-diastereomers, respectively, a plasma protein binding (ppb) of 67%, a systemic clearance of 417 mL.min-1 (S-diastereomer) and 191 mL.min-1 (R-diastereomer), and an elimination half-life (T1/2)of 12-18 hours. Pralatrexate is not significantly metabolized by the phase I hepatic CYP450 isozymes or phase II hepatic glucuronidases, and has low potential to induce or inhibit the activity of CYP450 isozymes - elimination is primarily of unchanged drug in urine. <br />
The recommended dosing of Pralatrexate is 30 mg.m-2 administrated as an intravenous injection once weekly for 6 weeks in 7-week cycles. The full prescribing information can be found <a href="http://www.folotyn.com/pdf/package-insert.pdf">here</a>. <br />
<a href="http://1.bp.blogspot.com/_GrFxGiayAGE/SsnvAA1Vo6I/AAAAAAAAAVc/ttgP3kn5IKA/s1600-h/Pralatrexate.png" onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5389101212628263842" src="http://1.bp.blogspot.com/_GrFxGiayAGE/SsnvAA1Vo6I/AAAAAAAAAVc/ttgP3kn5IKA/s400/Pralatrexate.png" style="cursor: pointer; display: block; height: 118px; margin: 0px auto 10px; text-align: center; width: 301px;" /></a><br />
The structure (2S)-2-[[4-[(1RS)-1-[(2, 4-diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amino]pentanedioic acid is a <a href="http://en.wikipedia.org/wiki/Folate">folate</a> analog in which the hydroxyl group of the pyrimidine ring has been replaced by an amine, and the central amino group of the molecule has been replaced by a stereocenter carbon with a methylacethylene attached to it (which may undergo nucleophilic atack). Pralatrexate diastereomers differ in configuration at this stereocenter only, and so they are also <a href="http://en.wikipedia.org/wiki/Epimer">epimers</a>. <br />
<pre>&lt;CHEMBL_DRUG&gt;
&lt;DRUG_NAME="Pralatrexate" TRADEMARK_NAME="Folotyn" APPROVAL_DATE="25-SEPT-2009" DRUG_MOLECULAR_WEIGHT=477.5&gt;
&lt;DRUG_STRUCTURE&gt;
&lt;DRUG_SMILES="O=C(O)[C@@H](NC(=O)c1ccc(cc1)C(CC#C)Cc2nc3c(nc2)nc(nc3N)N)CCC(=O)​O"&gt;
&lt;InChI="InChI=1/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18
(27-15)19(24)29-23( ​25)30-20)12-4-6-13(7-5-12)21(33)28-16
(22(34)35)8-9-17(31)32/h1,4-​ 7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,3​ 0)/t14?,16-/m0/s1"&gt;
&lt;InChIKey="OGSBUKJUDHAQEA-WMCAAGNKSA-N"&gt;
&lt;/DRUG_STRUCTURE&gt;
&lt;ChemDraw="Pralatrexate.cdx"&gt;
&lt;DRUG_TARGET&gt;
VGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFSI
PEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSSV
YKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKFE
VYEKND
&lt;/DRUG_TARGET&gt;
&lt;/CHEMBL_DRUG&gt;
</pre>The license holder is <a href="http://www.allos.com/">Allos Therapeutics, Inc.</a> and the product website is <a href="http://www.folotyn.com/">www.folotyn.com</a>.